AzTrials
AzTrials

Recurrent Prostate CancerPhase 2NCT07686380

IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

A Phase 2 study testing N-803, ETBX-71 Vaccine and 18F-DCFPyL in people with Recurrent Prostate Cancer and Prostate Cancer, run by National Cancer Institute (NCI) at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Background: Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blood rise after surgery or radiation. BCR affects 30,000 to 50,000 men each year. Read more about this study

Who is it for?
Ages 18 to 120 years, men only
Conditions the study is for
Recurrent Prostate Cancer, Prostate Cancer
What is being tested?
N-803, ETBX-71 Vaccine and 18F-DCFPyL
Could I receive a placebo?
No, everyone receives an active treatment
How many people
65 participants
Where
1 siteUnited States
Study dates
1 Oct 2026to 30 Jan 2029
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 120 years
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histopathological confirmation of prostate adenocarcinoma by the Laboratory of Pathology at the National Institutes of Health (NIH) Clinical Center prior to the study treatment initiation. If no pathologic specimen is available, participants may enroll with a pathologist s report showing a histologic diagnosis of prostate adenocarcinoma and a clinical course consistent with the disease from any outside site.
  • Biochemically recurrent prostate cancer, defined as PSA over 0.8 ng/ml following radical prostatectomy or >= 2 ng/ml above the nadir following definitive radiotherapy or definitive radiotherapy (including brachytherapy) for localized prostate cancer.
  • Participants must be at least 1 year removed from definitive local therapy before the study treatment initiation.
  • Recovery to baseline from acute toxicity related to prior therapy, including surgery and radiation.
  • Hepatic function eligibility parameters: Bilirubin (total and direct) <= upper limit of normal (ULN) (OR in participants with Gilbert s syndrome, a total bilirubin <= 3.0), aspartate transaminase (AST) and alanine transaminase (ALT) <= 1.5 times upper limit of normal.
  • Adequate renal function defined by a calculated creatinine clearance > 50 mL/min according to the Cockcroft-Gault formula or by measure of creatinine clearance from 24-hour urine collection.
Show all 20Show fewer
  • ECOG performance score 0-1.
  • No other active malignancies within the 36 months prior to the study treatment initiation (with the exception of nonmelanoma skin cancers or carcinoma in situ of the bladder).
  • 18 years of age or older.
  • Individuals must agree to use effective contraception (barrier, vasectomy and/or abstinence) for the duration of study therapy and for four months after the last treatment administration. Individuals with partners with birthing potential will be recommended that their partner use a highly effective contraception (includes use of oral, injected or implanted hormonal methods of contraception, placement of certain intrauterine devices (IUD) or intrauterine systems (IUS), hysterectomy, oophorectomy, salpingectomy.
  • Individuals must agree to not donate sperm during the restricted period (for the duration of study therapy and for four months after the last dose of study treatment).
  • Negative CT scan/ Magnetic resonance imaging (MRI) for evidence of soft tissue metastasis (visceral or lymph node).
  • Negative Tc99 for evidence of bone disease.
  • Participants must have had prior SBRT to PSMA+ findings beyond the prostate and have had a documented 25% or more PSA rise from post-SBRT nadir
  • Baseline testosterone >= 100 ng/dl.
  • Hematological parameters:
  • Granulocyte count >= 1000/mm^3
  • Platelet count >= 100000/mm^3
  • Hemoglobin (Hgb) >= 10 g/dL
  • Participants must be able to understand and willing to sign a written informed consent document.

Who cannot join

  • Immunocompromised status due to:
  • Human immunodeficiency virus (HIV) seropositivity
  • HBV or HCV seropositivity
  • Other immunodeficiency diseases
  • Active autoimmune diseases such as Addison's disease, Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren syndrome, scleroderma, myasthenia gravis, Goodpasture syndrome or active Grave's disease. Participants with a history of autoimmunity that has not required systemic immunosuppressive therapy or does not threaten vital organ function including central nervous system (CNS), heart, lungs, kidneys, skin, and gastrointestinal (GI) tract will be allowed. Participants with diabetes type I, vitiligo, or alopecia are allowed.
  • Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (e.g., corneal transplant, hair transplant).
Show all 14Show fewer
  • Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids within 28 days before the study treatment initiation. Note: Use of corticosteroids with minimal systemic absorption (e.g., inhaled steroids, nasal sprays, and topical agents) is allowed.
  • Other medications used for urinary symptoms including 5-alpha reductase inhibitors (finasteride and dutasteride) and alternative medications known to alter PSA (e.g., phytoestrogens and saw palmetto) within 28 days prior to the study treatment initiation.
  • Major surgery within 28 days prior to study treatment initiation.
  • Systemic therapy, including any investigational therapy within 28 days prior to the study treatment initiation.
  • Radiation therapy within 14 days prior to the study treatment initiation.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drugs.
  • Clinically significant cardiovascular/cerebrovascular disease as follows: cerebral vascular accident/stroke (< 6 months prior to the first planned dose of study drugs), myocardial infarction (< 6 months prior to the first planned dose of study drugs), or any of the following at time of enrollment: unstable angina, congestive heart failure (New York Heart Association Classification Class >= II), serious cardiac arrhythmia, or uncontrolled hypertension (SBP>170/ DBP>105).
  • Serious intercurrent medical illness evaluated by medical history and physical exam that would interfere with participant's ability to carry out the treatment program.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Amy R Hankin, P.A.-C contact

(240) 858-3149

amy.hankin@nih.gov

Melissa L Abel, M.D. contact

(240) 447-5353

melissa.abel@nih.gov

United States1 site, 1 recruiting

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892

    National Cancer Institute Referral Office, 888-624-1937, ncimo_referrals@mail.nih.gov

    Recruiting

Other trials in United States

About this study

Official title: Phase II Trial of IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

Background:

Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blood rise after surgery or radiation. BCR affects 30,000 to 50,000 men each year. Researchers want to know if a drug (N-803) alone or combined with a vaccine (ETBX-071) can reduce PSA in BCR prostate cancer after radiation.

Read more

Objective:

To test a study drug alone and combined with a vaccine in people with BCR prostate cancer who have been treated with targeted radiation to areas of recurrent prostate cancer in the past.

Eligibility:

People aged 18 years and older with BCR prostate cancer who have previously undergone treatment with stereotactic body radiation therapy (SBRT).

Design:

Participants will be screened. They will have a physical exam with blood tests. They will have tests of their heart and kidney function. They will have 3 different imaging scans of their tumors.

N-803 is injected under the skin of the abdomen. ETBX-071 is injected under the skin of thigh.

Participants will be divided into 2 groups: 1 group will get N-803 alone; 1 group will get both N-803 and ETBX-071.

The drug or drugs will be given on the first day of 21-day treatment cycles. Participants will have 8 treatment cycles.

Participants will have a follow-up visit 3 weeks after their last dose of the study drugs. Blood tests and all 3 imaging scans will be repeated.

Follow-up visits will continue every 4 to 8 weeks for 5 years. These visits will include a positron emission tomography (PET) scan every 6 months.

Read the detailed description

Background:

  • Biochemical recurrence (BCR) denotes rising prostate serum antigen (PSA) and negative computed tomography (CT) and Tc99 bone scan following radical prostatectomy and/or definitive local radiation.
  • Beyond local salvage radiation options, the management of BCR has not been clearly defined.
  • As BCR is an asymptomatic stage of disease which can take years to progress to overt metastatic disease, treatment for this stage should have minimal side effects and only be for a limited duration of time.
  • The advent of prostate-specific membrane antigen (PSMA)-based imaging has driven stereotactic body radiation therapy (SBRT) in BCR despite lack of robust evidence.
  • Further study is required to ascertain the role of SBRT in BCR.
  • Due to the presence of only microscopic disease, BCR may be the ideal stage of the disease to evaluate immunotherapy.
  • Previous studies in the GMB have demonstrated that vaccine can lead to delayed declines in PSA.
  • N-803 is an IL-15 superagonist which increases the number of natural killer (NK) and CD8 T cells without expanding regulatory T-cells. The net effect is to increase the inflammatory milieu of the tumor microenvironment and this is FDA approved for the treatment of superficial bladder cancer. There is clinical evidence of the activity of N-803 in prostate cancer.
  • The ETBX-071 is an adenoviral-based vaccine against PSA.
  • We have previously demonstrated the effects of vaccine in BCR. N-803 has demonstrated preclinical synergy with vaccine and has also been associated with PSA declines in a combination immunotherapy trial in metastatic prostate cancer.

Objectives:

-To estimate efficacy of N-803 alone or with ETBX-071 vaccine, each administered for 6 months, in participants with biochemically recurrent prostate cancer following PSA progression after SBRT

Eligibility:

  • Biochemically recurrent prostate cancer, defined as PSA over 0.8 ng/ml following radical prostatectomy or >= 2 ng/ml above the nadir following definitive radiotherapy.
  • No evidence of soft tissues disease on CT scan and bone metastasis on technetium-99m (Tc99) bone scan.
  • PSA rise of at least 25% of nadir following prior SBRT treatment for recurrent prostate cancer
  • Eastern Cooperative Oncology Group (ECOG) performance score 0-1.
  • No active or organ-threatening autoimmune disease.

Design:

  • This is an open-label phase 2 study in which all participants have received prior SBRT and experienced subsequent PSA progression.
  • Participants will be randomized between two treatments: N-803 for 6 months versus N-803 with ETBX-071 vaccine for 6 months.
Being tested
N-803, ETBX-71 Vaccine, 18F-DCFPyL
Keywords
Recurrent Prostate Cancer, IL-15 Superagonist, N-803, ETBX-071, PSA Vaccine
Medical subject headings
Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • N-803Drug

    15 mg/kg subcutaneous on Day 1 of every 3-week cycle for up to 8 cycles

  • ETBX-71 VaccineDrug

    The dose to be injected is 5(SqrRoot) 10^11 viral particles (VP) per 1 mL. Injected subcutaneously on Day 1 of every 3-week cycle for a total of up to 8 cycles

  • 18F-DCFPyLRadiation

    Single IV dose of 18F-DCFPyL by bolus injection. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi

Study groups in NCT07686380
Study groupRoleWhat they receive
N803ExperimentalN803
Receives: Drug: N-803; Radiation: 18F-DCFPyL
N803+ETBX-071 vaccineExperimentalN803+ETBX-071 vaccine
Receives: Drug: N-803; Drug: ETBX-71 Vaccine; Radiation: 18F-DCFPyL

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Efficacy of N-803 alone or with ETBX-071 vaccine

    PSA30 response- defined as a >= 30% reduction in PSA from PSA at C1D1 of immunotherapy (comparing C1D1 PSA to timepoints during and after immunotherapy). The fractions with PSA30 response will be reported along with a 95% confidence interval, separately for the two randomized treatment groups.

    Measured: D1 of each cycle of immunotherapy, at the end of treatment and every 4-8 weeks during follow-up until up to 5 years

Secondary outcomes (6)

  1. Duration of PSA50 response

    Duration of PSA response will be evaluated using the Kaplan-Meier method unless all participants are identified as having an end to their response (no censoring). The median duration of PSA response will be reported, starting at the date the PSA30 response was identified, along with a 95% confidence interval for the median, separately for the two randomized treatment groups.

    Measured: D1 of each cycle of immunotherapy, at the end of treatment and every 4-8 weeks during follow-up until up to 5 years

  2. Time to PSA progression

    Time to PSA progression after immunotherapy will be evaluated using the Kaplan-Meier method unless all participants are identified as having an end to their response (no censoring). The median time to PSA progression will be reported, starting at the date Cycle 1 began, along with a 95% confidence interval for the median.

    Measured: D1 of each cycle of immunotherapy, at the end of treatment and every 4-8 weeks during follow-up until up to 5 years

  3. PSA doubling timing

    PSA doubling time at randomization, compared to PSA doubling time at the end of treatment (EOT) visit.

    Measured: D1 of each cycle of immunotherapy, at the end of treatment and every 4-8 weeks during follow-up until up to 5 years

  4. Proportion of participants with 30% PSA decline receiving immunotherapy treatment after SBRT

    The median changes in PSA doubling time (in months) will be determined separately for both treatment groups with paired differences compared within participants using a Wilcoxon signed rank test.

    Measured: D1 of each cycle of immunotherapy, at the end of treatment and every 4-8 weeks during follow-up until up to 5 years

  5. Safety

    The number, grades, and types of adverse events will be reported separately for participants assigned to each treatment group using descriptive statistics.

    Measured: C1D1 of each cycle during immunotherapy and at the end of treatment

  6. Changes in PSMA PET scans

    These will be summarized descriptively.

    Measured: Prior to treatment, at end of treatment and in follow-up every 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jul 2026
  2. Study start1 Oct 2026
  3. Primary completion30 Jan 2029 (estimated)
  4. Study completion30 Jan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
65 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07686380
Sponsor's protocol ID
10002231
Other IDs
002231-C
Status last verified
23 Sep 2026
First submitted
3 Jul 2026
Last updated
6 Oct 2026
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: This study will comply with the NIH Data Management and Sharing (DMS) Policy, which applies to all new and ongoing NIH-funded research in the IRP, as of January 25, 2023, that is associated with a ZIA, with a clinical protocol that undergoes scientific review and/or will involve genomic data sharing.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing N-803, ETBX-71 Vaccine and 18F-DCFPyL in people with Recurrent Prostate Cancer and Prostate Cancer, run by National Cancer Institute (NCI) at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 20 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Amy R Hankin, P.A.-C ((240) 858-3149, amy.hankin@nih.gov), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Efficacy of N-803 alone or with ETBX-071 vaccine (time frame: D1 of each cycle of immunotherapy, at the end of treatment and every 4-8 weeks during follow-up until up to 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07686380.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in